You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic EGFR-mutant Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)

Recruiting
  • Lung Cancer Metastatic
  • EGFR Gene Mutation
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Orange,

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +8 more
  • Orange, California
  • +2 more
Aug 10, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Seoul, Gangnam-gu, Korea, Republic of
    Samsung Medical Center
Oct 27, 2023

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer Trial in United States (Amivantamab, Lazertinib)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Recurrent Non Small Cell Lung Cancer
  • Basking Ridge, New Jersey
  • +6 more
Aug 1, 2022

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Columbus

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jul 14, 2022

Non-Small-Cell Lung Cancer Trial in Shanghai (Furmonertinib (160mg))

Recruiting
  • Non-Small-Cell Lung Cancer
  • Furmonertinib (160mg)
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 2, 2022

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial (Poziotinib

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +3 more
  • Poziotinib Hydrochloride
  • 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
  • (no location specified)
Jul 18, 2022

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

Lung Cancer Trial in United States (Osimertinib, Platinum, Etoposide)

Recruiting
  • Lung Cancer
  • Basking Ridge, New Jersey
  • +6 more
Jul 1, 2022

Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • EGFR T790M
  • Seoul, Korea, Republic of
    Samsung Medical Center
May 18, 2022

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung

Recruiting
  • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Duarte, California
  • +14 more
Jan 27, 2023

NSCLC Stage IIIB~IV Trial in Taipei (Atezolizumab Injection; bevacizumab Injection)

Recruiting
  • NSCLC Stage IIIB~IV
  • Atezolizumab Injection; bevacizumab Injection
  • Taipei, Taiwan
    National Taiwan University Hospital
Jan 18, 2022

Non-Squamous NSCLC Trial in Guangzhou (AK112 Injection, Placebo Injection)

Recruiting
  • Non-Squamous Non-small Cell Lung Cancer
  • AK112 Injection
  • Placebo Injection
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 23, 2022

NSCLC Trial in Chattanooga, Nashville (Aumolertinib, Osimertinib)

Not yet recruiting
  • NSCLC
  • Chattanooga, Tennessee
  • +1 more
Aug 16, 2022

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Atlanta

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +4 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Mar 8, 2022

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

Metastatic NSCLC Trial in United States (Dacomitinib, Osimertinib)

Active, not recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Basking Ridge, New Jersey
  • +6 more
Dec 28, 2021

Non Small Cell Lung Cancer Trial in Seoul (Lazertinib , a combination group of SBRT, Lazertinib single administration group)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Lazertinib , a combination group of SBRT
  • Lazertinib single administration group
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 20, 2021

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Pembrolizumab
  • Ramucirumab
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 22, 2021

NSCLC, Lung Cancer, NSCLC Trial in United States (G1T38, Osimertinib)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Beverly Hills, California
  • +7 more
Sep 20, 2022

NSCLC Trial (AK119, AK112, Pemetrexed)

Not yet recruiting
  • NSCLC
  • (no location specified)
Nov 23, 2022

NSCLC (NSCLC) Trial in Taiwan (DS-1205c, Osimertinib)

Terminated
Has Results
  • Non-small Cell Lung Cancer (NSCLC)
  • New Taipei City, Taiwan
  • +6 more
Jan 10, 2022